23 . January , 2019 - Wednesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Gynazole-1

Big Image
Generic Name: butoconazole nitrate
Dosage Form: Vaginal cream

Rx Only
P4249-1      01/05

Gynazole-1 Description

Gynazole-1® (butoconazole nitrate) vaginal cream, 2% contains butoconazole nitrate 2%, an imidazole derivative with antifungal activity. Its chemical name is (±)-1-[4-(p-chlorophenyl)-2-[(2,6-dichlorophenyl) thio]butyl] imidazole mononitrate, and it has the following chemical structure:

Butoconazole nitrate is a white to off-white crystalline powder with a molecular weight of 474.79. It is sparingly soluble in methanol; slightly soluble in chloroform, methylene chloride, acetone, and ethanol; very slightly soluble in ethyl acetate; and practically insoluble in water. It melts at about 159°C with decomposition.

Gynazole-1® contains 2% butoconazole nitrate in a cream of edetate disodium, glyceryl monoisostearate, methylparaben, mineral oil, polyglyceryl-3 oleate, propylene glycol, propylparaben, colloidal silicon dioxide, sorbitol solution, purified water, and microcrystalline wax.

Gynazole-1 - Clinical Pharmacology

Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average. Peak plasma levels (13.6-18.6 ng radioequivalents/mL of plasma) of the drug and its metabolites are attained between 12 and 24 hours after vaginal administration.

Microbiology

The exact mechanism of the antifungal action of butoconazole nitrate is unknown; however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.

Butoconazole nitrate is an imidazole derivative that has fungicidal activity in vitro against Candida spp. and has been demonstrated to be clinically effective against vaginal infections due to Candida albicans. Candida albicans has been identified as the predominant species responsible for vulvovaginal candidasis.

Indications and Usage for Gynazole-1

Gynazole-1® (butoconazole nitrate) vaginal cream, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures (see CLINICAL STUDIES).

Note: Gynazole-1® is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established (see PRECAUTIONS: Pregnancy).

Contraindications

Gynazole-1® is contraindicated in patients with a history of hypersensitivity to any of the components of the product.

Clinical Studies

Vulvovaginal Candidiasis: Two studies were conducted that compared 2% butoconazole nitrate cream with clotrimazole tablets. There were 322 enrolled patients, 161 received 2.0% butoconazole vaginal cream and 161 patients inserted the 500-mg clotrimazole vaginal tablet. At the second follow-up visit (30 days post-therapy), 118 patients in the butoconzole group and 116 in the clotrimazole group were evaluable for efficacy analysis, respectively. All of these patients had infection caused by Candida albicans.

The efficacy of the study drugs was assessed by evaluating clinical, mycologic and therapeutic cure rates, which are summarized in Table 1.

The therapeutic cure was defined as complete resolution of signs and symptoms of vaginal candidiasis (clinical cure) along with a negative KOH examination and negative culture for Candida spp. (microbiologic eradication) at the long term follow-up. The therapeutic cure rate was 67% in the butoconazole group and 61% in the clotrimazole group.

Table 1
2% butoconazole nitrate cream 500-mg clotrimazole vaginal tablet
*=C. albicans in the vaginal culture was proven at admission in all of these patients.
Enrolled 161 161
Evaluable at Late Follow-up 118 116
Clinical Cure 95/118 (81%) 93/116 (80%)
Mycologic Eradication* 87/118 (74%) 77/116 (66%)
Therapeutic Cure 79/118 (67%) 71/116 (61%)

Warnings

This cream contains mineral oil. Mineral oil may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms; therefore, use of such products within 72 hours following treatment with Gynazole-1® is not recommended.

Recurrent vaginal yeast infections, especially those that are difficult to eradicate, can be an early sign of infection with the human immunodeficiency virus (HIV) in women who are considered at risk for HIV infection.

Precautions

General

If clinical symptoms persist, tests should be repeated to rule out other pathogens, to confirm the original diagnosis, and to rule out other conditions that may predispose a patient to recurrent vaginal fungal infections.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis: Long term studies in animals have not been performed to evaluate the carcinogenic potential of this drug.

Mutagenicity: Butoconazole nitrate was not mutagenic when tested in the Ames bacterial test, yeast, chromosomal aberration assay in CHO cells, CHO/HGPRT point mutation assay, mouse micronucleus, and rat dominant lethal assays.

Impairment of Fertility: No impairment of fertility was seen in rabbits or rats administered butoconazole nitrate in oral doses up to 30 mg/kg/day (5 times the human dose based on mg/M2) or 100 mg/kg/day (10 times the human dose based on mg/M2), respectively.

Pregnancy: Pregnancy Category C

In pregnant rats administered 6 mg/kg/day of butoconazole nitrate intravaginally during the period of organogenesis, there was an increase in resorption rate and decrease in litter size; however, no teratogenicity was noted. This dose represents a 130- to 353-fold margin of safety based on serum levels achieved in rats following intravaginal administration compared to the serum levels achieved in humans following intravaginal administration of the recommended therapeutic dose of butoconazole nitrate.

Butoconazole nitrate has no apparent adverse effect when administered orally to pregnant rats throughout organogenesis at dose levels up to 50 mg/kg/day (5 times the human dose based on mg/M2). Daily oral doses of 100, 300 or 750 mg/kg/day (10, 30 or 75 times the human dose based on mg/M2 respectively) resulted in fetal malformations (abdominal wall defects, cleft palate), but maternal stress was also evident at these higher dose levels. There were, however, no adverse effects on litters of rabbits who received butoconazole nitrate orally, even at maternally stressful dose levels (e.g., 150 mg/kg, 24 times the human dose based on mg/M2).

Butoconazole nitrate, like other azole anti-fungal agents, causes dystocia in rats when treatment is extended through parturition. However, this effect was not apparent in rabbits treated with as much as 100 mg/kg/day orally (16 times the human dose based on mg/M2).

There are, however, no adequate and well-controlled studies in pregnant women. Gynazole-1® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when butoconazole nitrate is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established.

Adverse Reactions

Of the 314 patients treated with Gynazole-1® for 1 day in controlled clinical trials, 18 patients (5.7%) reported complaints such as vulvar/vaginal burning, itching, soreness and swelling, pelvic or abdominal pain or cramping, or a combination of two or more of these symptoms. In 3 patients (1%) these complaints were considered treatment-related. Five of the 18 patients reporting adverse events discontinued the study because of them.

Gynazole-1 Dosage and Administration

The recommended dose of Gynazole-1® is one applicatorful of cream (approximately 5 grams of the cream) intravaginally. This amount of cream contains approximately 100 mg of butoconazole nitrate.

How is Gynazole-1 Supplied

Gynazole-1® (butoconazole nitrate) vaginal cream, 2% is available in cartons containing one single-dose prefilled disposable applicator.

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). (See USP Controlled Room Temperature.) Avoid heat above 30°C (86°F).

U.S. Patent Nos. 4,078,071, 4,551,148, 4,636,202 and 5,266,329

Manufactured for Ther-Rx Corporation
by KV Pharmaceutical Co.
St. Louis, MO  63044

Gynazole-1® (butaconazole nitrate) Vaginal Cream, 2%
In one prefilled disposable applicator

Using the Gynazole-1® Prefilled Disposable Applicator
3 Easy Steps:

Step 1: Preparing the Applicator

Peel back the protective foil and remove the prefilled applicator. Applicator is designed to be used with the tip in place. Do not remove the tip; do not use the applicator if the tip has been removed.

Do not warm applicator before using. While holding the applicator firmly, pull the ring back to fully extend the plunger (See Figure 2).

Step 2: Inserting the Applicator

Gently insert the applicator into the vagina as far as it will comfortably go (See Figure 3).

Step 3: Applying the Cream

Push the plunger to release the cream (See Figure 4). Remove the empty applicator from the vagina and throw it away.

Important Instructions:

  • One prefilled applicator of Gynazole-1® should be administered.
  • This cream contains mineral oil. Mineral oil may weaken latex or rubber products such as condoms or vaginal contraceptives, diaphragms; therefore, use of such products within 72 hours following treatment with Gynazole-1® is not recommended.
  • There are no adequate and well-controlled studies in pregnant women. Gynazole-1® should be used during pregnancy only under the supervision of a physician.

P4249-1 01/05


Gynazole-1 (Butoconazole Nitrate)
PRODUCT INFO
Product Code 64011-001 Dosage Form CREAM
Route Of Administration VAGINAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Butoconazole Nitrate (Butoconazole Nitrate) Active 20 MILLIGRAM  In 1 GRAM
colloidal silicon dioxide Inactive  
edetate disodium Inactive  
glyceryl Inactive  
methylparaben Inactive  
microcrystalline wax Inactive  
mineral oil Inactive  
monoisostearate Inactive  
polyglyceryl-3 oleate Inactive  
propylene glycol Inactive  
propylparaben Inactive  
water Inactive  
sorbitol solution Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 64011-001-08 5 GRAM In 1 APPLICATOR None

Revised: 03/2007

Recent Drug Updates at DrugIndexOnline:





brompheniramine and phenylpropanolamine brompheniramine and phenylpropanolamine
Generic Name: brompheniramine and phenylpropanolamine (brome feh NEER a meen/fen ill proe pa NO la meen) Brand Names: Altatapp, Dibrom, Dibromm, Dimaphen, Dimetapp, Myphetapp What is brompheniramine and phenylpropanolamine? Brompheniramine is an antihistamine. It works against the natura more...

Canesten Combi-Pak 3-Day Therapy Vaginal Canesten Combi-Pak 3-Day Therapy Vaginal
Some commonly used brand names are: In the U.S.— FemCare 2 Femizol-M 4 Femstat 3 1 Gyne-Lotrimin 2 Gyne-Lotrimin Combination Pack 2 Gyne-Lotrimin3 2 Gyne-Lotrimin3 Combination Pack 2 Miconazole-7 4 Monistat 1 6 Monistat 1 Combination Pack 4 Monistat 3 4 Monistat 3 Combination Pack 4 Monis more...

Cardizem Cardizem
Generic Name: Diltiazem Injection (dil-TYE-a-zem) Brand Name: CardizemCardizem is used for:Treating supraventricular tachycardia, a rhythm disturbance of the heart. It is also used for controlling heart rate response to other rhythm disturbances, specifically, atrial fibrillation and flutter. I more...

Doxepin Concentrate Doxepin Concentrate
Generic Name: Doxepin Oral Concentrate (DOX-e-pin) Brand Name: SinequanAntidepressants may increase the risk of suicidal thoughts or actions in children and teenagers. The risk may be greater during the first few months that patients take Doxepin Concentrate. Be sure that the benefits of using D more...

Duotan PD Duotan PD
Generic Name: dexchlorpheniramine and pseudoephedrine (dex klor fen EER a meen and soo doe e FED rin) Brand Names: AllerDur, Duotan PD, Tanafed DP What is Duotan PD (dexchlorpheniramine and pseudoephedrine)? Dexchlorpheniramine is an antihistamine that reduces the natural chemical hista more...

Histex HC Liquid Histex HC Liquid
Generic Name: Carbinoxamine/Hydrocodone/Pseudoephedrine Liquid (car-bihn-OCKS-ah-meen/hye-droe-KOE-done/sue-do-eh-FED-rin) Brand Name: Examples include Histex HC and Mintex HCHistex HC Liquid is used for:Relieving symptoms of sinus congestion, runny nose, sneezing, and cough due to colds, upper more...

Moricizine Moricizine
Some commonly used brand names are: In the U.S.— Ethmozine † Not commercially available in Canada. Category Antiarrhythmic Description Moricizine (mor-IH-siz-een) belongs to the group of medicines known as antiarrhythmics. It is used to correct irregular or rapid heartbeat more...

NeoCitran DM Coughs and Colds NeoCitran DM Coughs and Colds
Some commonly used brand names are: In the U.S.— Alka-Seltzer Plus Cold and Cough 21 Alka-Seltzer Plus Cold and Cough Medicine Liqui-Gels 34 Alka-Seltzer Plus Night-Time Cold Liqui-Gels 35 Ami-Tex LA 69 Anatuss LA 70 Benylin Expectorant 54 Bromfed-DM 17 Broncholate 68 Carbinoxamine Compou more...